An engineer in South Korea has lost 30 papers, at least seven of which for duplication and plagiarism. He has also been fired from his university position.
Soon-Gi Shin, whose affiliation was listed as Kangwon National University in Gangwon, is the sole author on the majority of the papers, published in four journals between 2000 and 2015.
Taewan Kim, the dean of international affairs at the university, told Retraction Watch that Shin was fired on August 21, 2017, over “violation[s] of research ethics.”
For a host of reasons, a journal has retracted a paper co-authored by a researcher who reportedly once faced charges of practicing medicine without proper qualifications.
Originally published June 17, 2016, the paper was retracted Jan. 15. Led by corresponding author Xavier Altafaj, of the University of Barcelona (UB) and Bellvitge Biomedical Research Institute (IDIBELL), researchers described using an amino acid, D-serine, to treat a child with a rare genetic disorder that affects neurons.
According to the notice, the researchers did use D-serine in lab work used as proof-of-concept; however, when it came time to try it in the patient, as a result of a “communication error:”
In 2004, a survey of editors of economic journals found 3 out of 10 had seen at least one case of plagiarism within the past year. More than a decade later, has the problem gotten better? Or worse? Gary Hoover at the University of Oklahoma, who co-authored the 2004 paper, decided to revisit the issue by resurveying editors in economics, along with others working in different fields. What he found — and reported in Social Science Quarterly — was plagiarism is still a problem, which economists want to address.
A biology journal has retracted a 2011 paper after the University of California, Los Angeles determined that the data in three figures “cannot be supported.”
In February, the journal Applied and Environmental Microbiology retracted the paper, which explores efforts to engineer bacteria to convert plant biomass into biofuel.
Nowadays, there are many ways to access a paper — on the publisher’s website, on MEDLINE, PubMed, Web of Science, Scopus, and other outlets. So when the publisher retracts a paper, do these outlets consistently mark it as such? And if they don’t, what’s the impact? Researchers Caitlin Bakker and Amy Riegelman at the University of Minnesota surveyed more than one hundred retractions in mental health research to try to get at some answers, and published their findings in the Journal of Librarianship and Scholarly Communication. We spoke to Bakker about the potential harm to patients when clinicians don’t receive consistent notifications about retracted data.
Retraction Watch: You note: “Of the 144 articles studied, only 10 were represented as being retracted across all resources through which they were available. There was no platform that consistently met or failed to meet all of [the Committee on Publication Ethics (COPE)’s] guidelines.” Can you say more about these findings, and the challenges they may pose?
A researcher who is facing a criminal investigation in Italy for research misconduct has seen five more papers retracted, for a total of 16 15.
Molecular and Cellular Biology has retracted four papers published between 1987 to 2001 by Alfredo Fusco, a cancer researcher in Italy; the Journal of Virology retracted one 1985 paper. Fusco was first author on two papers and last author on three. Both journals are published by The American Society for Microbiology (ASM), which issued identical retraction notices for all five papers, mentioning “evidence of apparent manipulation and duplication.”
Carlo Croce, a cancer researcher now at the Ohio State University, who has been dogged by misconduct allegations, co-authored one of the papers. Croce now has eight retractions.
When Nicholas Peppas, chair of engineering at the University of Texas at Austin, discovered one of his papers had been plagiarized, he decided to “go public!”
When Alexander Harms arrived at the University of Copenhagen in August 2016, as a postdoc planning to study a type of antibiotic resistance in bacteria, he carried with him a warning from another lab who had recruited him:
People said, “If you go there, you have to deal with these weird articles that nobody believes.”
The papers in question had been published in the Proceedings of the National Academy of Sciences in 2011 and Cell in 2013. Led by Kenn Gerdes, Harms’s new lab director, the work laid out a complex chain of events that mapped out how an E. coli bacterium can go into a dormant state, called persistence, that allows it to survive while the rest of its colony is wiped out.
Despite some experts’ skepticism, each paper had been cited hundreds of times. And Harms told us:
I personally did believe in the published work. There had been papers from others that kind of attacked [the Gerdes lab’s theory], but that was not high-quality work.